Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Syndrome | D013577 | — | — | 1 | 2 | — | — | — | 3 |
Mitochondrial diseases | D028361 | EFO_0000591 | — | — | 1 | — | — | — | 1 |
Muscular diseases | D009135 | EFO_0002970 | G72.9 | — | 1 | — | — | — | 1 |
Inborn errors lipid metabolism | D008052 | — | — | — | 1 | — | — | — | 1 |
Hearing loss | D034381 | EFO_0004238 | H91.9 | — | 1 | — | — | — | 1 |
Noise-induced hearing loss | D006317 | EFO_1001254 | — | — | 1 | — | — | — | 1 |
Deafness | D003638 | EFO_0001063 | H91.9 | — | 1 | — | — | — | 1 |
Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 1 | — | — | — | 1 |
Autism spectrum disorder | D000067877 | — | F84.0 | — | 1 | — | — | — | 1 |
Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tourette syndrome | D005879 | EFO_0004895 | F95.2 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Optic nerve diseases | D009901 | EFO_1001330 | H47.14 | — | — | — | — | 1 | 1 |
Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
Hereditary optic atrophy leber | D029242 | Orphanet_104 | H47.22 | — | — | — | — | 1 | 1 |
Drug common name | Vatiquinone |
INN | vatiquinone |
Description | Vatiquinone is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)=CCC/C(C)=C/CC/C(C)=C/CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |
PDB | — |
CAS-ID | 1213269-98-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1812161 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 6O85FK9I0X (ChemIDplus, GSRS) |